Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- New Osaka Logistics Center to Go Live in January: Taisho
December 12, 2013
- Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
- US FDA Advisory Panel Backs Takeda Ulcerative Colitis Drug
December 11, 2013
- Santen Sets Up Local Subsidiary in Singapore
December 11, 2013
- Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
- Ono to Launch PI Study on Peptide-Cocktail Vaccine for HCC
December 11, 2013
- GSK Launches Asthma Treatment Relvar
December 11, 2013
- Drug Makers Invest in Developing AD Treatments
December 10, 2013
- Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
- Santen Files MAA for Ciclosporin for Dry Eye Disease in Europe
December 10, 2013
- Veep Kawasaki to Be Elevated to President of inVentiv Health Japan
December 9, 2013
- Survey Finds 1.7-Fold Increase in Patients Prescribed DPP-4 Inhibitors Over 2-Year Period: MDV
December 9, 2013
- ViiV Healthcare Files NDA for Anti-HIV Treatment Dolutegravir in Japan
December 9, 2013
- “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End
December 9, 2013
- Fujifilm to Initiate Joint PII Study of AD Treatment with ADCS
December 9, 2013
- Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use
December 6, 2013
- Kyowa Kirin Shutters Yokkaichi Plant
December 6, 2013
- M3 to Make Mediscience Planning Its Wholly Owned Subsidiary
December 6, 2013
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
- Takeda to Market Teva’s Multiple Sclerosis Treatment in Japan
December 5, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…